Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Bipolar Disorder
NCT00221481Phase 4Withdrawn
- Sponsor
- Mayo Clinic
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in alcohol use disorder (AUD) and bipolar disorder (BD) comparing Divalproex sodium with Olanzapine (2 arms). Primary endpoint: Alcohol abuse relapse up to 46 weeks. Status: withdrawn.
02
Drugs
divalproex sodiumolanzapine
03
Conditions
alcohol use disorder (AUD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00221481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00221481.